(Total Views: 510)
Posted On: 04/25/2021 8:48:15 AM
Post# of 153819
I think there are several revenue paths this year based on the shift announced in the video by NP a few days ago. It was a small
comment he made but a strategic shift in my mind . NP mentioned they want revenue for the current patients using Virologix for HIV. This shift recognizes they are truly a business and cannot be a charity organization . I would look for Cytodyn to ask the FDA for revenue on patients of the phase 2 trial once the trial is over. Should the patients show great improvement but they may need more shots for maintenance, I see revenue here.I also believe they will push for revenue in trial efforts in Brazil and India , just as they are getting paid for the CSP in the Philippines.
And one last opportunity , I also believe the phase 3 Longhaulers trial will be large and will require investment from a partner who will pay for the trial and also sign a licensing and sales agreement with Cytodyn for the LH application..
comment he made but a strategic shift in my mind . NP mentioned they want revenue for the current patients using Virologix for HIV. This shift recognizes they are truly a business and cannot be a charity organization . I would look for Cytodyn to ask the FDA for revenue on patients of the phase 2 trial once the trial is over. Should the patients show great improvement but they may need more shots for maintenance, I see revenue here.I also believe they will push for revenue in trial efforts in Brazil and India , just as they are getting paid for the CSP in the Philippines.
And one last opportunity , I also believe the phase 3 Longhaulers trial will be large and will require investment from a partner who will pay for the trial and also sign a licensing and sales agreement with Cytodyn for the LH application..
(5)
(0)
